OBJECTIVES: Ceftaroline fosamil (CPT, TEFLARO ® ) is a new, broad-spectrum, bactericidal cephalosporin approved in the US for the treatment of community-acquired bacterial pneumonia (CABP). In two randomized controlled CABP trials (NCT00621504, NCT00509106), clinical cure rates in the modified intent-to-treat (MITT) efficacy population were 82.6% for CPT and 76.6% for ceftriaxone. Response rates at Day 4 (MITT population, Nϭ141) were 69.6% and 58.3% for CPT and ceftriaxone. The objective was to assess the budgetary impact of adding CPT to a US hospital formulary. METHODS: A three-year hospital budget impact model was constructed to evaluate patients hospitalized with CABP requiring intravenous (IV) antimicrobial therapy and having PORT risk class scores of III or IV. Patients were randomized to receive CPT 600mg IV q12h or 1g ceftriaxone IV q24h for 5-7 days. Clinical cure rates were assumed to be similar to those from CPT phase 3 CABP trials. Patients failing initial treatment were assumed to be treated successfully with second-line antibiotic therapy. Length of stay and total cost per hospital day (by success or failure with initial treatment) were estimated based on a large database from over 100 US hospitals. Other model inputs included: annual number of CABP admissions; projected annual case growth rate; proportion of CABP target population initially treated with ceftriaxone; expected proportion of CABP target population to be treated with CPT; drug cost; cost of antibiotic administration; cost of second-line antibiotic therapy for patients failing initial therapy. A sensitivity analysis using 95% confidence limits of clinical cure rates from phase 3 trials provided varying estimates. RESULTS: Estimated total cost for treating a CABP patient with CPT is $1102 lower ($18,925 vs. $20,027) than treating a similar patient with ceftriaxone (sensitivity analysis range: -$6 to -$2,223). CONCLUSIONS: Model estimates indicate adding ceftaroline to formulary does not negatively impact a hospital CABP budget.
PIN9 A GERMAN HOSPITAL BUDGET IMPACT MODEL COMPARING ANTIBIOTIC THERAPIES IN COMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS AND BACTEREMIA
Jensen IS 1 , Ogborne R 2 , Cyr PL 1 1 Navigant, Inc., Boston, MA, USA, 2 Navigant, Inc., London, UK OBJECTIVES: Daptomycin is a cyclic lipopeptide antibiotic that has been commercially available in Europe since 2006. Daptomycin has rapid bactericidal activity against MRSA and is indicated for gram-positive infections including complicated skin and skin structure infections (cSSSI), right-sided infective endocarditis and Staphylococcus aureus bacteremia (BSI). This study aims to quantify the budgetary impact of utilizing Daptomycin for suspected gram-positive cSSSI and BSI in Germany. METHODS: A budget impact model was developed to compare the total direct costs of utilizing vancomycin, linezolid, daptomycin, and "other antibiotics" as a single category. A decision tree was constructed on the basis of clinical guidelines and validated by clinicians. Clinical data and laboratory utilization and cost data were derived from a comprehensive review of over 40 publications. Antibiotic utilization and net drug costs were derived using syndicated data from Arlington Medical Resources (AMR). RESULTS: On average, the total direct costs (drug acquisition, lab monitoring, and hospital) of treating a cSSSI patient with the following agents were: vancomycin €2598 (4%, 12% and 84%), linezolid €2742 (37%, 5%, and 58%), daptomycin €3,171 (30%, 7%, and 63%), and other antibiotics €1835 (2%, 10%, and 88%). For BSI patients, total direct costs were: vancomycin €2359 (5%, 13% and 82%), linezolid €3951 (37%, 5%, and 58%), daptomycin €2135 (37%, 7%, and 56%), and other antibiotics €3087 (4%, 10%, and 86%). Extrapolating these costs to an average German hospital with 300 BSI and 1000 cSSSI patients and increasing daptomycin use in BSI from 1% to 6% and in cSSSI from 0.3% to 1.4% would save the hospital €30,151 and €2,971 per year, respectively. CONCLUSIONS: Using daptomycin for treating cSSSI is budget neutral and using it for bacteremia patients is associated with favorable economic outcomes when compared with other antibiotics. ) is a new, broad-spectrum, bactericidal cephalosporin approved in the United States for the treatment of acute bacterial skin and skin structure infections (ABSSSI). In two randomized controlled ABSSSI trials (NCT00424190, NCT00423657), clinical cure rates in the modified intent-to-treat (MITT) population were 85.9% with CPT and 85.5% with vancomycinϩ aztreonam. Clinical response rates at Day 3 (MITT population, Nϭ797) were 74.0% and 66.2% for CPT and vancomycin ϩ aztreonam combination, respectively. The objective was to assess the budgetary impact of adding CPT to a hospital formulary in the United States. METHODS: A three-year hospital budget impact model was constructed with three initial treatment options; CPT, vancomycin ϩ aztreonam, and other vancomycin-containing regimens. The target population was hospitalized adult, ABSSSI patients. Clinical cure rates with initial treatment were assumed to be similar to those from CPT clinical trials. Patients failing initial treatment were assumed to be treated successfully with a second-line antibiotic therapy. Length of stay and cost per hospital day (by success or failure with initial treatment) were estimated based on a large database from over 100 US hospitals. Other model inputs included: annual number of ABSSSI admissions; projected annual case growth rate; proportion of ABSSSI target population receiving vancomycin-containing regimen; expected proportion of ABSSSI target population to be treated with CPT; drug acquisition cost; cost of antibiotic administration; cost of vancomycin monitoring. A sensitivity analysis using 95% confidence limits of clinical cure rates provided varying estimates. RESULTS: Estimated total cost for treating an ABSSSI patient with CPT is $313 lower ($13,804 vs. $14,117) than vancomycin ϩ aztreonam (sensitivity analysis range; ϩ$235 to -$833) and $71 lower ($13,804 vs. $13,875) than other vancomycin-containing regimens (sensitivity analysis range; ϩ$478 to -$1430). CONCLUSIONS: Model estimates indicate adding ceftaroline to formulary does not negatively impact a hospital ABSSSI budget. Pfizer, Inc., New York, NY, USA, 5 Pfizer, Inc., Collegeville, PA, USA, 6 Pfizer, Inc., Groton, CT, USA OBJECTIVES: Assess economic costs of adverse events (AEs) among patients with human immunodeficiency virus (HIV) treated with non-nucleoside reverse transcriptase inhibitors (NNRTIs) including delavirdine, efavirenz, etravirine, and nevirapine. METHODS: Retrospective cohort study using medical and pharmacy claims from US commercial or Medicare supplemental insurance patients between January 1, 2004 to September 30, 2009. Adult HIV-patients initiating NNRTI (no NNRTI use during 6 months prior to first dispensation [index date]) were selected. AEs included rash, nausea/vomiting, diarrhea, dizziness, headache, sleep-related symptoms, hepatotoxicity, lipid disorders, depression, anxiety, and self-injury. AE episode-related care during the year post-initiation was identified by claims associated with AE management. AE cases were matched 1:4 to non-AE controls by propensity of having an AE. "Associated costs" included plan payments and patient copayments directly related to managing AEs. "Incremental costs" of experiencing an AE were calculated as the difference in total costs between patients with AE during the period of each AE episode and non-AE controls (matched period).
PIN10 THE ECONOMIC IMPACT OF ADDING CEFTAROLINE FOSAMIL TO A US HOSPITAL FORMULARY FOR ACUTE BACTERIAL SKIN AND SKIN STRUCTURE INFECTIONS

PIN11
COSTS OF ADVERSE EVENTS AMONG PATIENTS WITH HUMAN IMMUNODEFICIENCY VIRUS TREATED WITH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
RESULTS:
The study included 2548 NNRTI users (mean age 43 years; 84% male; 87% efavirenz; 29% experienced an AE). During 1-year post-index period, annual total healthcare cost per patient in this study population was $27,751 (efavirenz: $26,704; other NNRTIs: $34,993). Annual mean AE associated costs were $609 per patient (efavirenz: $555; other NNRTIs: $979). Mean AE associated cost of care (duration) per AE episode ranged from $586 (88 days) for lipid disorders, $975 (33 days) for A238 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 -A 2 5 6
